momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (11691)	9/24/2018 12:20:40 PM
From: Miljenko Zuanic	Read Replies (1) of 12215

In light of the today AMRN's Vascepa results and MH note in Forbes (https://www.forbes.com/sites/matthewherper/2018/09/24/in-blowout-amarins-fish-oil-derived-drug-dramatically-cuts-heart-risk-in-study/#3f152ef04f27), I am more convicted than ever that THR-beta agonist (2809 and 3196) are far more SUPERIOR (triglyceride, ApoB, Lp-a,...) than ANY Omega-3 product in CVD/NASH, TD-2 settings. My research (DD) 2-years ago were correct,..... while I did projected Vascepa failure (non-statistical reduction in MACE, not more than 10%..relative like Imrove-IT). So, I was wrong on VASCEPA! or, maybe not.....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next